This reversal effect of PAR2 inhibition was further uncovered in enhancing gefitinib to modulate NSCLC cell migration and apoptosis (Figure 2, Supplementary Figure S3). This evidence concerns the gene F2RL1 and non-small cell lung carcinoma.